Loading...
•
Mar 31, 2024
Collegium Q1 2024 Earnings Report
Collegium reported first quarter 2024 financial results.
Key Takeaways
Collegium Pharmaceutical reported a successful first quarter in 2024, with net revenues of $144.9 million and a GAAP net income of $27.7 million. The company delivered record Belbuca revenue of $50.7 million and reaffirmed its full-year 2024 guidance.
Generated Q1 2024 net revenue of $144.9 million.
Delivered Q1 2024 record Belbuca revenue of $50.7 million, with total prescriptions up 4.2% year-over-year.
Achieved Q1 2024 GAAP net income of $27.7 million, compared to a net loss of $(17.4) million in Q1 2023.
Delivered Q1 2024 Adjusted EBITDA of $92.4 million, up 5% year-over-year.
Revenue by Segment
Forward Guidance
The Company reaffirms its full-year 2024 guidance for Product Revenues, Net, Adjusted Operating Expenses and Adjusted EBITDA
Positive Outlook
- Product Revenues, Net $580.0 to $595.0 million
- Adjusted Operating Expenses (Excluding Stock-Based Compensation) $120.0 to $125.0 million
- Adjusted EBITDA (Excluding Stock-Based Compensation) $380.0 to $395.0 million
- Authorized generic agreement with Hikma improves the value of the Nucynta Franchise.
- Healthy balance sheet fortifies our financial position.
Challenges Ahead
- Transition of CEO.
- Uncertainty of the expected financial performance of products.
- Success of competing products that are or become available.
- Ability to maintain regulatory approval of products, and any related restrictions, limitations, and/or warnings in the label of products.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...